180 related articles for article (PubMed ID: 31359797)
1. Current and future clinical utilities of Parkinson's disease and dementia biomarkers: can they help us conquer the disease?
Ho G; Takamatsu Y; Waragai M; Wada R; Sugama S; Takenouchi T; Fujita M; Ali A; Hsieh MH; Hashimoto M
Expert Rev Neurother; 2019 Nov; 19(11):1149-1161. PubMed ID: 31359797
[No Abstract] [Full Text] [Related]
2. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's and Lewy body dementia CSF biomarkers.
Parnetti L; Paciotti S; Farotti L; Bellomo G; Sepe FN; Eusebi P
Clin Chim Acta; 2019 Aug; 495():318-325. PubMed ID: 31051162
[TBL] [Abstract][Full Text] [Related]
5. PD and DLB: Brain imaging in Parkinson's disease and dementia with Lewy bodies.
Berman SB; Miller-Patterson C
Prog Mol Biol Transl Sci; 2019; 165():167-185. PubMed ID: 31481162
[TBL] [Abstract][Full Text] [Related]
6. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
7. Alpha-Synuclein as a Biomarker for Parkinson's Disease.
Atik A; Stewart T; Zhang J
Brain Pathol; 2016 May; 26(3):410-8. PubMed ID: 26940058
[TBL] [Abstract][Full Text] [Related]
8. Motor performance differentiates individuals with Lewy body dementia, Parkinson's and Alzheimer's disease.
Fritz NE; Kegelmeyer DA; Kloos AD; Linder S; Park A; Kataki M; Adeli A; Agrawal P; Scharre DW; Kostyk SK
Gait Posture; 2016 Oct; 50():1-7. PubMed ID: 27544062
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers of Parkinson's Disease: An Introduction.
Titova N; Qamar MA; Chaudhuri KR
Int Rev Neurobiol; 2017; 132():183-196. PubMed ID: 28554407
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia.
Noe E; Marder K; Bell KL; Jacobs DM; Manly JJ; Stern Y
Mov Disord; 2004 Jan; 19(1):60-7. PubMed ID: 14743362
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
Stav AL; Aarsland D; Johansen KK; Hessen E; Auning E; Fladby T
Parkinsonism Relat Disord; 2015 Jul; 21(7):758-64. PubMed ID: 25971633
[TBL] [Abstract][Full Text] [Related]
12. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action.
Athauda D; Foltynie T
Drug Discov Today; 2016 May; 21(5):802-18. PubMed ID: 26851597
[TBL] [Abstract][Full Text] [Related]
13. Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease.
Goldman JG; Aggarwal NT; Schroeder CD
Neurodegener Dis Manag; 2015 Oct; 5(5):425-43. PubMed ID: 26517759
[TBL] [Abstract][Full Text] [Related]
14. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
15. Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?
Le W; Dong J; Li S; Korczyn AD
Neurosci Bull; 2017 Oct; 33(5):535-542. PubMed ID: 28866850
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Serum Lipidomics for Detecting Incipient Dementia in Parkinson's Disease.
Zardini Buzatto A; Tatlay J; Bajwa B; Mung D; Camicioli R; Dixon RA; Li L
J Proteome Res; 2021 Aug; 20(8):4053-4067. PubMed ID: 34251208
[TBL] [Abstract][Full Text] [Related]
17. Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.
DeMarshall CA; Han M; Nagele EP; Sarkar A; Acharya NK; Godsey G; Goldwaser EL; Kosciuk M; Thayasivam U; Belinka B; Nagele RG;
Immunol Lett; 2015 Nov; 168(1):80-8. PubMed ID: 26386375
[TBL] [Abstract][Full Text] [Related]
18. Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients.
Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Tang BS; Wang CY
J Clin Neurosci; 2019 Dec; 70():198-201. PubMed ID: 31492481
[TBL] [Abstract][Full Text] [Related]
19. Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study.
Levy G; Tang MX; Cote LJ; Louis ED; Alfaro B; Mejia H; Stern Y; Marder K
Mov Disord; 2002 Mar; 17(2):250-7. PubMed ID: 11921109
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for the diagnosis and management of Parkinson's disease.
Waragai M; Sekiyama K; Fujita M; Tokuda T; Hashimoto M
Expert Opin Med Diagn; 2013 Jan; 7(1):71-83. PubMed ID: 23530844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
